NCT05218499 2026-03-02
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Phase 2/3 Completed
Clinical Trials
10 trialsNCT02451943 2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3 Completed
NCT06115681 2025-07-10
Real-world Study of Dedifferentiated Liposarcoma Patients in China
Boehringer Ingelheim
Completed
NCT05580588 2025-06-13
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Shanghai Pharma Biotherapeutics USA Inc.
Phase 2 Terminated
NCT04979442 2025-01-14
MANTRA
Rain Oncology Inc
Phase 3 Terminated
NCT04996004 2024-12-11
TTI-621-03
Pfizer
Phase 2 Terminated
NCT02606461 2023-01-23
SEAL
Karyopharm Therapeutics Inc
Phase 2/3 Completed
NCT02609984 2020-07-07
IMDZ-C232
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated
NCT00060944 2014-09-08
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00579501 2014-05-07
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed